Daily adaptive MR-guided stereotactic ablative re-irradiation (re-SABR) in oligometastatic liver disease: A single-institution retrospective analysis
With the limitation of relatively low patient numbers and mixed tumour histology, MR-guided re-SABR to oligometastatic liver disease appeared well tolerated, achieving high LC rates. DIR-based workflow predicted higher cumulative OAR doses, potentially further improving the safety of liver re-SABR.
Authors
- Elena Moreno-Olmedo (ORCID: https://orcid.org/0000-0001-7508-1544)
- James Good (ORCID: https://orcid.org/0000-0002-6960-5345)
- Kasia Owczarczyk (ORCID: https://orcid.org/0000-0001-7413-0949)
- Paul Bassett (ORCID: https://orcid.org/0000-0001-7830-4563)
- Ramanivas Sundareyan (ORCID: https://orcid.org/0000-0002-8906-8890)
- Andy Gaya
- D. Stark Murray (ORCID: https://orcid.org/0009-0002-1059-9742)
- Veni Ezhil
- Somnath Mukherjee (ORCID: https://orcid.org/0000-0002-7202-0698)
- Ben George (ORCID: https://orcid.org/0000-0002-6263-5891)
- P. Dickinson (ORCID: https://orcid.org/0000-0001-7562-7973)
- R. Muirhead
Institutions
- Genesis HealthCare (US)
- Oxford University Hospitals NHS Trust (GB)
- 21c Consultancy (United Kingdom) (GB)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.ctro.2025.101082
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00